GTC has a new publication in Heliyon titled “The Potential of Cell-Free RNA in Liquid Biopsy: Comprehensive Analysis of Mutation Profile, Chromosomal Abnormalities, and Immune Biomarkers”. This study explores the potential of cell-free RNA (cfRNA) and AI as valuable components of liquid biopsy for evaluating the host immune system and
Baltimore, MD and Irvine, CA, April 13, 2023, Sysmex Inostics Inc., a subsidiary of Japan’s Sysmex Corporation and Baltimore-based biotechnology firm, and Genomic Testing Cooperative (GTC), based in Irvine, California, formed a strategic partnership for Sysmex Inostics to commercialize GTC’s tissue and liquid biopsy solid tumors and hematology assay services
Demonstrating Reliability of Targeted Transcriptomic Profiling in Predicting Levels of HER2, ER, PD-L1 and Other Immunohistochemistry-based Biomarkers when Combined with Artificial Intelligence Irvine, California– April 11, 2023 – Genomic Testing Cooperative, LCA (GTC) announced that it will be presenting data at the 2023 American Association of Cancer Research (AACR) Annual
CHICAGO – With the publication of a paper validating two artificial intelligence-based algorithms for assisting pathologists in molecular profiling of patients, the Genomic Testing Cooperative (GTC) is fully implementing the technology at all of its member laboratories. The paper, which appeared earlier this month in the American Journal of Pathology, delved into
GTC research is being presented at ASCO 2020 in the following three abstracts. 1. FGFR expression, fusion and mutation as detected by NGS sequencing of DNA and RNA. * 2. Measuring PD-L1 mRNA expression using targeted next generation sequencing and correlation with interferon pathway activation genes in lung and colorectal
GTC featured in the Orange County Business Journal on September 30, 2019
Genomic Testing cooperative (GTC) provides a comprehensive genomic profiling of breast cancer including evaluating: – Actional mutations– Gene amplification and deletion– Hormonal expression levels– Microsatellite stability (MSI)– Tumor mutation burden (TMB)– Homologous recombination deficiency (HRD) status and homologous recombination repair (HRR) gene testing The GTC tests for breast cancer (Liquid
MDS is defined as ineffective hematopoiesis characterized by adequate or increased hematologic elements in bone marrow with peripheral cytopenia. Therefore, the presence of cytopenia in one or more hematologic lines is necessary for the diagnosis of MDS. However, numerous reactive conditions other than MDS can cause cytopenia and these conditions
(FOR UPDATED INFORMATION ABOUT COMPREHENSIVE TESTING FOR BREAST CANCER VISIT THIS PAGE: Comprehensive testing for breast cancer evaluating DNA and RNA) When you order GTC Breast Cancer Profile The FDA has approved Piqray (alpelisib) tablets, to be used in combination with the FDA-approved endocrine therapy fulvestrant, to treat postmenopausal women,
The FDA has approved Balversa (erdafitinib) as a treatment for adult patients with locally advanced or metastatic bladder cancer that have FGFR3 or FGFR2 abnormalities and that has progressed during or following prior platinum-containing chemotherapy. Urothelial tumors have been reported to show abnormalities in FGFR3 (22%), FGFR1 (8%), and FGFR2
